- Home
- SNDX vs SPH Comparison
SNDX vs SPH Comparison
Compare SNDX & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- SPH
- Stock Information
- Founded
- SNDX 2005
- SPH 1945
- Country
- SNDX United States
- SPH United States
- Employees
- SNDX N/A
- SPH N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- SPH Other Specialty Stores
- Sector
- SNDX Health Care
- SPH Consumer Discretionary
- Exchange
- SNDX Nasdaq
- SPH Nasdaq
- Market Cap
- SNDX 1.1B
- SPH 1.2B
- IPO Year
- SNDX 2016
- SPH 1996
- Fundamental
- Price
- SNDX $9.60
- SPH $18.48
- Analyst Decision
- SNDX Strong Buy
- SPH Sell
- Analyst Count
- SNDX 11
- SPH 1
- Target Price
- SNDX $34.18
- SPH $17.00
- AVG Volume (30 Days)
- SNDX 2.0M
- SPH 182.3K
- Earning Date
- SNDX 07-31-2025
- SPH 08-07-2025
- Dividend Yield
- SNDX N/A
- SPH 6.98%
- EPS Growth
- SNDX N/A
- SPH N/A
- EPS
- SNDX N/A
- SPH 1.46
- Revenue
- SNDX $43,722,000.00
- SPH $1,424,243,000.00
- Revenue This Year
- SNDX $426.77
- SPH $10.99
- Revenue Next Year
- SNDX $98.31
- SPH N/A
- P/E Ratio
- SNDX N/A
- SPH $12.76
- Revenue Growth
- SNDX N/A
- SPH 4.02
- 52 Week Low
- SNDX $8.58
- SPH $15.20
- 52 Week High
- SNDX $25.07
- SPH $22.24
- Technical
- Relative Strength Index (RSI)
- SNDX 48.99
- SPH 48.05
- Support Level
- SNDX $8.59
- SPH $18.05
- Resistance Level
- SNDX $10.01
- SPH $18.71
- Average True Range (ATR)
- SNDX 0.54
- SPH 0.45
- MACD
- SNDX 0.10
- SPH 0.03
- Stochastic Oscillator
- SNDX 71.48
- SPH 39.94
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.